Tag: G1 Therapeutics
December 20, 2018
G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib
G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data showing multi-lineage myelopreservation benefits in its randomized, double-blind,...
November 27, 2018
G1 Therapeutics Releases Phase 2 Data
Trilaciclib was tested in combination with chemotherapy and the checkpoint inhibitor Tecentriq in first-line small cell lung cancer patients. November 27, 2018
G1 Therapeutics Announces Positive Myelopreservation Data
G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data from its randomized, double-blind, placebo-controlled Phase 2 trial evaluating...
October 22, 2018
8 Top Gains and Losses at 2018’s ESMO Event
Big Pharma players and smaller oncology-focused companies alike were among the presenters at the annual meeting, which runs from October... April 16, 2018
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38,... March 8, 2018
G1 Therapeutics Announces Pricing of Offering of Common Stock
G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of... March 5, 2018